Status:
RECRUITING
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Lead Sponsor:
Shanghai Cell Therapy Group Co.,Ltd
Conditions:
Relapsed
Refractory
Eligibility:
All Genders
18-75 years
Phase:
EARLY_PHASE1
Brief Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients wit...
Detailed Description
This is a single arm, open-label, dose escalation investigator initiated (IIT) study, the primary objective is to evaluate the safety and tolerability of CD19/ CD22/BCMA CAR-T therapy in patients with...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
December 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 12 2027
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06732232
Start Date
December 12 2024
End Date
December 12 2027
Last Update
December 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China, Shanghai Mengchao Cancer Hospital
Shanghai, China